ABSTRACT
Background Association between inflammation and depression has been known for a long time. Activation of pro-inflammatory molecular complexes such as inflammasomes in depression was suggested as the most relevant hypothesis among many others. Psychological stress is considered to cause sterile inflammation through inflammasomes, and the NLRP3 inflammasome was proposed as a crucial molecule for the pro-inflammatory response in depression.
Objective In the current study, we aimed to explore the relationship of NLRP3 inflammasome and its regulatory protein NEK7 with major depressive disorder in a drug naïve study sample.
Methods In total 58 patients with major depressive disorder and 58 age and gender-matched healthy persons were included. The mRNA expressions of NLRP3, ASC, caspase-1 and NEK7 coding proteins were evaluated with quantitative PCR, plasma IL-1β levels were detected by ELISA.
Results Patients with major depressive disorder had higher gene expressions of NLRP3 (p= 0.03) and ASC (p= 0.002) compared to healthy persons. Higher gene expressions of NLRP3 (OR= 1.17, 95% CI= 1.01, 1.37, p= 0.04), ASC (OR= 1.45, 95% CI= 1.15, 1.82, p= 0.002) and NEK7 (OR= 1.33, 95% CI= 1.08, 1.63, p= 0.007) were related to the increased likelihood of having major depressive disorder.
Conclusion The results of this study support the role of NLRP3 inflammasome in the increased risk for major depressive disorder.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by a grant from the Scientific and Technological Research Council of Turkey (TUBITAK) (project number: 218S271).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Dokuz Eylul University School of Medicine gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵1 Department of Organismal Biology, Uppsala University, Uppsala, Sweden, fatih.ozel{at}ebc.uu.se
↵2 The Interdisciplinary Research Center Womher, Uppsala University, Uppsala, Sweden
↵3 Department of Psychiatry, Cesme Alper Cizgenakat State Hospital, Izmir, Turkey
↵4 Istanbul Faculty of Medicine, Department of Psychiatry, Istanbul University, Istanbul, Turkey, nese.direk{at}istanbul.edu.tr
Data Availability
All data produced in the present study are available upon reasonable request to the authors.